Close Menu

Two years ago, Pfizer announced it had partnered with biotech company Celldex to develop a brain cancer vaccine. At the time, many people thought the move heralded the beginning of pharmaceutical companies developing personalized treatments for patients, says Robert Langreth on Forbes' Treatments blog. But now Pfizer has dissolved the partnership, leaving Celldex to try and develop the drug on its own.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bloomberg reports the US Centers for Medicare & Medicaid Services sent Orig3n a letter saying it has not corrected lab issues uncovered in an earlier inspection.

In an editorial at BMJ Opinion, two genetic counselors call for an increased focus on post-test patient care.

A new survey finds people in the US are getting their COVID-19 test results back faster, but not fast enough to help some viral control measures, NPR reports.

In PLOS this week: genomic analysis of malaria parasites in Ethiopia, loci linked to childhood BMI, and more.